Summary by Moomoo AI
Ming Kand Pharmaceutical published a special audit report on 18 March 2024, with unreserved comments from Dak Kin Huayong Accounting Firm. The report covers the current situation of non-operating capital allocation and other related funds in 2023 and is reconciled with the 2023 financial statements and found no significant inconsistencies. The report is prepared in accordance with the regulatory requirements of institutions such as the China Securities and Exchange Commission and aims to disclose the use of funds by the controlling shareholders, the actual controllers and other related parties. Ming Kand said that in order to improve the efficiency of its capital management, it has signed a capital pool business management agreement with its subsidiary and the bank to achieve uniform management of funds and will report the net amount of borrowing from its subsidiary.